서울대학교 중앙도서관

S-Space 소개

My S-Space

로그인이 필요합니다.

Login

S-Space

Browse

Subject

Jump to a point in the index

Or type in a year

Sort by
In order
Results/Page
Authors/record

Showing results 1 to 9 of 9

Issue Date	Title / Author(s) / Citation	File	Altmetrics
2015-12	Mechanisms of Acquired Resistance to AZD9291 A Mutation-Selective, Irreversible EGFR Inhibitor Kim, Tae Min; Song, Ahnah; Kim, Dong-Wan; Kim, Soyeon; Ahn, Yong-Oon; Keam, Bhumsuk; Jeon, Yoon Kyung; Lee, Se-Hoon; Chung, Doo Hyun; Heo, Dae Seog Journal of Thoracic Oncology, Vol.10 No.12, pp.1736-1744	DOI
2018-03	Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer Ramalingam, Suresh S.; Yang, James C. -H.; Lee, Chee Khoon; Kurata, Takayasu; Kim, Dong-Wan; John, Thomas; Nogami, Naoyuki; Ohe, Yuichiro; Mann, Helen; Rukazenkov, Yuri; Ghiorghiu, Serban; Stetson, Daniel; Markovets, Aleksandra; Barrett, J. Carl; Thress, Kenneth S.; Janne, Pasi A. Journal of Clinical Oncology, Vol.36 No.9, pp.841-849	DOI
2019-06	NK92-CD16 cells are cytotoxic to non-small cell lung cancer cell lines that have acquired resistance to tyrosine kinase inhibitors Park, Ha-Ram; Ahn, Yong-Oon; Kim, Tae Min; Kim, Soyeon; Kim, Seulki; Lee, Yu Soo; Kim, Miso; Keam, Bhumsuk; Kim, Dong-Wan; Heo, Dae Seog Cytotherapy, Vol.21 No.6, pp.603-611	DOI
2019-09	Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations Lee, Yusoo; Kim, Tae Min; Kim, Dong-Wan; Kim, Soyeon; Kim, Miso; Keam, Bhumsuk; Ku, Ja-Lok; Heo, Dae Seog Journal of Thoracic Oncology, Vol.14 No.9, pp.1556-1566	DOI
2020-02	Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: The BLOOM study Yang, James C. H.; Kim, Sang-We; Kim, Dong-Wan; Lee, Jong-Seok; Cho, Byoung Chul; Ahn, Jin-Seok; Lee, Dae H.; Kim, Tae Min; Goldman, Jonathan W.; Natale, Ronald B.; Brown, Andrew P.; Collins, Barbara; Chmielecki, Juliann; Vishwanathan, Karthick; Mendoza-Naranjo, Ariadna; Ahn, Myung-Ju Journal of Clinical Oncology, Vol.38 No.6, pp.538-547	DOI
2020-03	Real-world use of osimertinib in non-small cell lung cancer: ASTRIS study Korean subgroup analysis Cho, Byoung Chul; Kim, Dong-Wan; Park, Keunchil; Lee, Jong-Seok; Yoo, Seung Soo; Kang, Jin Hyoung; Lee, Sung Yong; Kim, Cheol Hyeon; Jang, Seung Hun; Kim, Young-Chul; Yoon, Hyoung-Kyu; Han, Ji-Youn; Kim, Sang-We Current Medical Research and Opinion, Vol.36 No.3, pp.477-482	DOI
2020-06	Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study Tan, Daniel S-W; Leighl, Natasha B.; Riely, Gregory J.; Yang, James C-H; Sequist, Lecia, V; Wolf, Juergen; Seto, Takashi; Felip, Enriqueta; Aix, Santiago P.; Jonnaert, Maud; Pan, Chun; Tan, Eugene Y.; Ko, Jinnie; Moody, Susan E.; Kim, Dong-Wan The Lancet Respiratory Medicine, Vol.8 No.6, pp.561-572	DOI
2021-11	Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFR(T790M)-Mutant NSCLC Park, Ha-Ram; Kim, Tae Min; Lee, Yusoo; Kim, Soyeon; Park, Seongyeol; Ju, Young Seok; Kim, Miso; Keam, Bhumsuk; Jeon, Yoon Kyung; Kim, Dong-Wan; Heo, Dae Seog Journal of Thoracic Oncology, Vol.16 No.11, pp.1859-1871	DOI
2022-01	Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non–Small Cell Lung Cancer Lee, Chaelin; Kim, Miso; Kim, Dong-Wan; Kim, Tae Min; Kim, Soyeon; Im, Sun-Wha; Jeon, Yoon Kyung; Keam, Bhumsuk; Ku, Ja-Lok; Heo, Dae Seog Cancer Research and Treatment, Vol.54 No.1, pp.140-149	DOI

1